News

Investigators conclude that policies seeking to lower rates of diabetes may also contribute to the goal of ending tuberculosis.

Observational cohort study evaluated nearly 900 school-age children to identify how these symptoms vary by age and how they can assist in future research of long COVID.

New vaccine is tailored to the KP.2 strain, based on regulatory guidance for upcoming fall and winter season.

Elinzanetant was found to significantly lower the frequency and severity of moderate to severe vasomotor symptoms with statistically significant improvements in sleep disturbances and menopause-related quality of life.

Trial will evaluate Galapagos’ GLPG5101, an autologous CD19 CAR-T cell therapy product candidate.

Mild or moderate acute kidney injury has been linked to increased morbidity and mortality, with a greater risk of chronic kidney disease in patients who undergo cardiac surgery with cardiopulmonary bypass.

In the third and final part of this conversation, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara sheds light on industry collaboration and what elements of trial design have the greatest impact on diversity.

The pivotal Phase III OASIS 1 and 2 studies both met all primary endpoints with elinzanetan reducing symptoms over 12 weeks compared to placebo.

In part 2 of this conversation, Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses the guidance and how it will affect sponsors moving forward.

A higher percentage of patients with advanced clear-cell renal cell carcinoma administered Welireg were alive and without disease progression compared to everolimus at 12 and 18 months.

In part 1 of this video interview, Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara highlights how IROs are bringing care directly to patients and making them feel more comfortable.

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.

Phase III REST-ON trial data show higher rates of weight loss in patients administered Lumryz to treat both narcolepsy type 1 (with cataplexy) and narcolepsy type 2 (without cataplexy) compared with placebo.

Approval is based off results from the Phase III MARIPOSA study, which showed Rybrevant in cominbation with Lazcluze reduced the risk of disease progression or death by 30% versus osimertinib.

Valued up to $100 million, the collaboration will conduct clinical trials over a five-year period with the goal of strengthening decentralized models.

Patients administered tirzepatide (Zepbound and Mounjaro; Eli Lilly) also achieved sustained weight loss in Phase III trial, with individuals administered the 15 mg dose showing a 22.9% average reduction in body weight compared with 2.1% among those receiving placebo.

Cohort study shows Xtandi (enzalutamide) achieved statistically significant improvements in overall survival vs. abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer.

In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.

Incyte’s Monjuvi (tafasitamab) met its primary endpoint of progression free survival in the study.

Results from the joint Phase III clinical trial of the vaccine also demonstrated results comparable to the companies’ licensed COVID-19 vaccine.

In part 4 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how the regulators are addressing new technology with updated guidances.

Priority review of Imfinzi was based on promising results from the ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based concurrent chemoradiotherapy.

In part 3 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA touches on how the right technology for your study should alleviate site burden and improve data quality.

In part 2 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA discusses how advancements in technology are creating challenges with integration and how they can be addressed.

Q&A with Joachim Lövin explores the challenges and lessons learned in boosting the flexibility of conducting decentralized clinical trials post-COVID.

Results demonstrated prolonged progression free survival of two patients in Acclaim-1 study and partial remission from maintenance therapy in Acclaim-3 study.

Results from the Phase III MONeT clinical trial found that Abrysvo was well tolerated in adults over the age of 18 years old.

New investigators practicing in community-based settings bring enthusiasm and a fresh approach to clinical research, while also boosting collaboration and merging personal connection and patient-centric insights.

In part 1 of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA highlights how patients, sites, and sponsors can benefit from recent advancements such as AI and LLMs.

Designing eConsent for each study from a stakeholders’ value, not technology perspective.